摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-碘-7-氮杂吲哚 | 898746-50-4

中文名称
5-碘-7-氮杂吲哚
中文别名
5-碘-1H-吡咯并[2,3-b]吡啶
英文名称
5-iodo-1H-pyrrolo[2,3-b]pyridine
英文别名
——
5-碘-7-氮杂吲哚化学式
CAS
898746-50-4
化学式
C7H5IN2
mdl
MFCD06659679
分子量
244.035
InChiKey
CYMDPTJBUBTWEY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    196-197°C
  • 密度:
    2.082±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    28.7
  • 氢给体数:
    1
  • 氢受体数:
    1

安全信息

  • 危险等级:
    IRRITANT
  • 危险品标志:
    Xi
  • 危险类别码:
    R22
  • WGK Germany:
    3
  • 海关编码:
    2933990090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:b1a689dc00f130909f1a6bb2d661fb03
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 5-Iodo-1h-pyrrolo[2,3-b]pyridine
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 5-Iodo-1h-pyrrolo[2,3-b]pyridine
CAS number: 898746-50-4

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H5IN2
Molecular weight: 244.0

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen Iodide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

5-碘-7-氮杂吲哚是一种5-卤代氮杂环吲哚。这类化合物特别是5-氯代和5-溴代氮杂环吲哚,在医药化工领域具有重要意义,可以用于合成Roche公司研发的抗癌药物Vemurafenib(Zelboraf,维罗非尼)以及Novartis公司开发的SGS-393等药物。

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] PYRROLO [2, 3. B] PYRIDINES WHICH INHIBIT RAF PROTEIN KINASE<br/>[FR] PYRROLO [2, 3. B] PYRIDINES QUI INHIBENT LA PROTÉINE KINASE RAF
    申请人:PLEXXIKON INC
    公开号:WO2010129567A1
    公开(公告)日:2010-11-11
    Compounds (I) and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, and forms thereof are active on each of BRaf and c-Raf -1 protein kinase, and may also be active on either or both of A-Raf and B-Raf V600E protein kinase. Also described are methods of use thereof to treat diseases and conditions, including melanoma, colorectal cancer, thyroid cancer, ovarian cancer, and biliary tract cancer.
    描述了化合物(I)及其盐,配方,结合物,衍生物,形式和用途。在某些方面和实施例中,所述的化合物或其盐,配方,结合物,衍生物和形式对BRaf和c-Raf -1蛋白激酶均具有活性,并且也可能对A-Raf和B-Raf V600E蛋白激酶中的一个或两个具有活性。还描述了使用这些方法来治疗疾病和病况,包括黑色素瘤,结直肠癌,甲状腺癌,卵巢癌和胆道癌。
  • Compounds and methods for kinase modulation, and indications therefor
    申请人:Plexxikon Inc.
    公开号:US09096593B2
    公开(公告)日:2015-08-04
    Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, or forms thereof are active on Fms protein kinase, or on Fms and Kit protein kinase, or on Fms and Flt-3 protein kinase. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of Fms protein kinase, Kit protein kinase, or Flt-3 protein kinase including rheumatoid arthritis, osteoarthritis, multiple sclerosis, Alzheimer's disease, Parkinson's disease, glomerulonephritis, interstitial nephritis, Lupus nephritis, tubular necrosis, diabetic nephropathy, renal hypertrophy, acute myeloid leukemia, melanoma, multiple myeloma, metastatic breast cancer, prostate cancer, pancreatic cancer, neurofibromatosis, brain metastases, and gastrointestinal stromal tumors.
    描述了化合物及其盐,制剂,共轭物,衍生物,形式和用途。在某些方面和实施方式中,所述的化合物或其盐,制剂,共轭物,衍生物或形式对Fms蛋白激酶,或对Fms和Kit蛋白激酶,或对Fms和Flt-3蛋白激酶具有活性。还描述了使用方法,用于治疗与Fms蛋白激酶,Kit蛋白激酶或Flt-3蛋白激酶活性相关的疾病和状况,包括类风湿性关节炎,骨关节炎,多发性硬化症,阿尔茨海默病,帕金森病,肾小球肾炎,间质性肾炎,狼疮性肾炎,小管坏死,糖尿病肾病,肾肥大,急性髓性白血病,黑色素瘤,多发性骨髓瘤,转移性乳腺癌,前列腺癌,胰腺癌,神经纤维瘤病,脑转移和胃肠间质瘤。
  • COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
    申请人:Plexxikon Inc.
    公开号:US20160326162A1
    公开(公告)日:2016-11-10
    Compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein R 1 , R 2 , Q 1 , Q 2 , and Q 3 , are described in this disclosure, compositions thereof, and methods and uses thereof.
    公式I的化合物:或其药用可接受的盐、溶剂化合物、互变异构体、同分异构体或氘代物,其中R1、R2、Q1、Q2和Q3在本公开中有描述,以及其组合物、方法和用途。
  • Discovery of a Novel Series of Potent and Selective Alkynylthiazole-Derived PI3Kγ Inhibitors
    作者:Upul K. Bandarage、Alex M. Aronov、Jingrong Cao、Jon H. Come、Kevin M. Cottrell、Robert J. Davies、Simon Giroux、Marc Jacobs、Sudipta Mahajan、David Messersmith、Cameron S. Moody、Rebecca Swett、Jinwang Xu
    DOI:10.1021/acsmedchemlett.0c00573
    日期:2021.1.14
    family of enzymes that control a wide variety of cellular functions such as cell growth, proliferation, differentiation, motility, survival, and intracellular trafficking. PI3Kγ plays a critical role in mediating leukocyte chemotaxis as well as mast cell degranulation, making it a potentially interesting target for autoimmune and inflammatory diseases. We previously disclosed a novel series of PI3Kγ inhibitors
    磷酸肌醇 3-激酶 (PI3K) 是一个酶家族,可控制多种细胞功能,例如细胞生长、增殖、分化、运动、存活和细胞内运输。PI3Kγ 在介导白细胞趋化性和肥大细胞脱粒中起关键作用,使其成为自身免疫和炎症性疾病的潜在有趣靶标。我们之前披露了一系列源自苯并噻唑核心的新型 PI3Kγ 抑制剂。苯并噻唑核心的截断导致发现了结构多样的炔基噻唑系列,该系列显示出高 PI3Kγ 效力和亚型选择性。炔基噻唑系列的进一步药物化学优化导致化合物如14和32的鉴定、高效、亚型选择性和 CNS 渗透性 PI3Kγ 抑制剂。化合物14在体内显示出对 PI3Kγ 介导的嗜中性粒细胞迁移的强烈抑制。
  • [EN] COMPOUNDS AS BCL-2 INHIBITORS<br/>[FR] COMPOSÉS EN TANT QU'INHIBITEURS DE BCL-2
    申请人:FOCHON PHARMACEUTICALS LTD
    公开号:WO2021223736A1
    公开(公告)日:2021-11-11
    Provided are certain Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
    提供了特定的Bcl-2抑制剂,其药物组成物以及使用方法。
查看更多

同类化合物

(4aS-反式)-八氢-1H-吡咯并[3,4-b]吡啶 骆驼蓬酸 顺-六氢-1H-吡咯并[3,2-B]吡啶-4(2H)-羧酸叔丁基酯 螺哌啶-4,3’-3H吡咯并[2,3-b]吡啶-2’(1’H)-酮 螺[哌啶-4,3'-吡咯并[2,3-B]吡啶]-2'(1'H)-酮盐酸盐 莫西沙星杂质69 苹果酸法米替尼 苯乙胺,a,4-二甲基-b-苯基- 苄基-11氢吡咯并[3,4-B]吡啶 罗沙布林 甲基6-甲酰基-1-甲基-1H-吡咯并[3,2-b]吡啶-2-羧酸酯 甲基5-氰基-1H-吡咯并[2,3-b]吡啶-2-羧酸酯 甲基1H-吡咯并[2,3-B]吡啶-5-甲酸酯 甲基-1-甲氧基-4-吡咯并[3,2-c]吡啶 甲基 5-硝基-1H-吡咯并[2,3-B]吡啶-2-羧酸 环戊二烯并[4,5]吡咯并[2,3-B]吡啶,5,6,7,8-四氢 氧代-(1H-吡咯并[2,3-b]吡啶-3-基)-乙酸甲酯 培西达替尼盐酸盐 培西达替尼 吲嗪 吲哚嗪-6-羧酸乙酯 吲哚嗪-3-甲腈 吲哚嗪-2-羧酸甲酯 吲哚嗪-2-羧酸 叔丁基八氢-1H-吡咯并[2,3-c]吡啶-6-羧酸盐 叔丁基5-溴-7-氯-3-碘-1H-吡咯并[2,3-c]吡啶-1-羧酸盐 叔丁基5-溴-7-氯-1H-吡咯并[2,3-c]吡啶-1-羧酸盐 叔丁基3-甲酰基-5-甲基-1H-吡咯并[2,3-b]吡啶-1-羧酸盐 叔丁基3-(3-羟丙基-1-炔基)-5-甲基-1H-吡咯并[2,3-b]吡啶-1-羧酸盐 叔丁基(5-甲基-1H-吡咯并[2,3-b]吡啶-3-基)氨基甲酸酯 叔丁基((5-氟代-1H-吡咯并[2,3-b]吡啶-4-基)甲基氨基甲酸酯 反式-六氢-1H-吡咯并[3,4-C]吡啶-5(6H)-羧酸叔丁酯 化合物 T28221 八氢吡咯并[3.4-b]吡啶-1-羧酸叔丁酯 八氢吡咯并[3,4-b]吡啶 八氢-吡咯[3,4-C]吡啶-2-甲酸叔丁酯 八氢-6-(苯基甲基)-1H-吡咯并[3,4-b]吡啶-1-羧酸 1,1-二甲基乙酯 八氢-1H-吡咯并[3,4-C]吡啶 二苯基(吡咯并[2,3-b]吡啶-1-基)膦 二乙基1H-吡咯并[2,3B]吡啶-2,6-二甲酸基酯 乙基7-氯-3-甲基-1H-吡咯并[3,2-b]吡啶-2-甲酸基酯 乙基7-氮杂吲哚-4-羧酸酯 乙基4-(4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷-2-基)-1H-吡咯并[2,3-b]吡啶-2-羧酸酯 乙基3-氨基-2-吲嗪羧酸酯 乙基1-乙基-1H-吡咯并[3,2-c]吡啶-6-羧酸酯 中氮茚-7-羧酸甲酯 中氮茚-6-羧酸 中氮茚-1-甲酸甲酯 中氮茚-1-甲酸 中氮茚,1-[[4-(3-溴丙氧基)苯基]磺酰]-2-乙基-